Recombinant Human Insulin-like growth factor-binding protein 3 protein(IGFBP3) (Active)

In Stock
Code CSB-AP002491HU
Size US$3274Purchase it in Cusabio online store
(only available for customers from the US)
Image
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >98% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/ml, corresponding to a specific activity of >5.0x103 IU/mg in the presence of 15 ng/ml of rHuIGF-II.
Target Names IGFBP3
Uniprot No. P17936
Research Area Cancer
Alternative Names Acid stable subunit of the 140 K IGF complex; Binding protein 29; Binding protein 53; BP 53; BP53; Growth hormone dependent binding protein; IBP 3; IBP-3; IBP3; IBP3_HUMAN; IGF binding protein 3; IGF-binding protein 3; IGFBP 3; IGFBP-3; IGFBP3; Insulin Like Growth Factor Binding Protein 3; Insulin-like growth factor binding protein 3 precursor; Insulin-like growth factor-binding protein 3
Species Homo sapiens (Human)
Source E.coli
Expression Region 28-291aa(A32G,S148E)
Complete Sequence GASSGGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK
Mol. Weight 28.8 kDa
Protein Length Full Length of Mature Protein
Tag Info Tag-Free
Form Lyophilized powder
Buffer Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 5-10 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.
Gene References into Functions
  1. In cancerous tissues of colorectal cancer (CRC) patients, the miR197 level was inversely correlated with the expression of IGFBP3, which indicated that miR197 may modulate cell migration and invasion by targeting IGFBP3 in CRC patients. PMID: 30106114
  2. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression. PMID: 28393842
  3. B-Myb is an independent prognostic marker and serves as a potential target in the diagnosis and/or treatment of NSCLC, and that B-Myb functions as a tumor-promoting gene by targeting IGFBP3 in NSCLC cells. PMID: 29772705
  4. IGFBP-3 up-regulates PI3K/Akt/mTOR signaling pathway and down-regulates autophagy during cell aging. The decrease of IGFBP-3 expression in senescence and cell aging by H2O2 leads to up-regulation of mTOR and p53 signaling pathway, suggesting that IGFBP-3 could play a key role as an aging marker PMID: 29579543
  5. Low IGFBP-3 serum levels were associated with Pancreatic Cancer. PMID: 28681154
  6. IGFBP-3 Interacts with the Vitamin D Receptor in Insulin Signaling Associated with Obesity in Visceral Adipose Tissue PMID: 29112142
  7. IGFBP3, a gene associated with preeclampsia pathophysiology, was validated as a target gene of miR-210 PMID: 28653360
  8. analysis of IGFBP3-IGF1 correlation with the risk of esophageal carcinoma; the free form of IGFBP3, might be inversely associated with esophageal cancer incidence PMID: 28596684
  9. Our data indicate that targeting IGFBP-3-dependent signaling pathways through gefitinib-FTY720 co-therapy may be effective in many basal-like breast cancers, and suggest tissue IGFBP-3 and CD44 measurement as potential biomarkers of treatment efficacy. PMID: 28778177
  10. Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional ERalpha and endocrine responsiveness. Assessing ERalpha function (e.g., IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen PMID: 28073843
  11. In longitudinal analysis, changes of FGF-21 were not significantly related to changes of height, IGF-1 or IGFBP-3 in obese children. PMID: 26887040
  12. the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH PMID: 28300542
  13. We confirmed a previously reported association between circulating IGFBP-3 and diabetes risk in the older adult population PMID: 29040592
  14. The results of this study, while not clearly supporting associations between these obesity-related biomarkers and renal cell carcinoma risk, are consistent with previously reported findings for adiponectin, and suggest an association with elevated IGFBP-3 among obese individuals PMID: 28484923
  15. our results reveal a new function of IGFBP2, providing a novel insight into the mechanism of adipogenic differentiation and identifying a potential target mediator for improving adipose tissue engineering based on Wharton's jelly of the umbilical cord (WJCMSCs). PMID: 28859160
  16. Increased IGFBP3 level as associated with decreased risk of frailty in men. PMID: 28609827
  17. Functional IGFBP-3 was significantly lower in postmenopausal women than in premenopausal women, for both patients with rheumatoid arthritis and controls. There was a significant decrease in plasma functional IGFBP-3 levels in postmenopausal RA in comparison to healthy premenopausal subjects. PMID: 27775453
  18. study suggests high-order interactions of the IGFBP-3 rs2854744 AA genotype, BMI>/=24kg/m2, and DISI<9.85 mg/day on increased BC risk, particularly among postmenopausal women PMID: 27631779
  19. The stratification of individuals by gender revealed that Slovak males carrying IGFBP-3 G alleles (G32G or GG) had marginally increased risk for developing MDD as compared to CC homozygous males (p=0.09). In women, inverse association was observed between SNP rs1042522 and MDD risk (p=0.04 for recessive model). PMID: 27755861
  20. results indicate that hypoxia suppresses the osteogenic differentiation of mesenchymal stem cells via IGFBP3 up-regulation. PMID: 27563882
  21. Meta-analysis suggests that for esophageal cancer, the low IGFBP-3 level is associated with high cancer risk, poor prognosis, and unfavorable tumor stage and metastasis. [meta-analysis] PMID: 27978831
  22. Expression of IL-24 and IGFBP-3 significantly suppressed prostate cancer tumor growth in vivo. PMID: 26323436
  23. Blood IGFBP3 was lower in Black participants compared to Whites. PMID: 27455178
  24. The microRNA-125b level promotes invasive ability in p53-mutated cells via PI3K/AKT activation by targeting of insulin-like growth factor-binding protein-3. PMID: 28378642
  25. High expression of IGFBP3 is associated with metastasis in nasopharyngeal carcinoma. PMID: 27658775
  26. results indicated that miR-197 targeted IGFBP3 to induce the overgrowth and anti-apoptotic effects of Wilms tumor cells PMID: 27223680
  27. There is no interaction between IGFBP3 and MTA1 in ESCC, and they are not independent risk factors for esophageal squamous cell carcinoma prognosis. PMID: 27035126
  28. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma PMID: 26670461
  29. Study showed that IGFBP3 is dramatically induced in pancreatic tumors, and is abundantly produced in pancreatic cancer cells, causing muscle wasting through both impaired myogenesis via, at least, inhibition of IGF/PI3K/AKT signaling. PMID: 26975989
  30. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells via integrin beta1 signaling. PMID: 26540630
  31. endogenous IGFBP-3 is a p53 target that plays a role in breast cancer cell responsiveness to DNA damaging therapy PMID: 26378048
  32. Data indicate that IGF-binding protein 3 (IGFBP3) and F3 gene expression levels in formalin fixed paraffin embedded (FFPE) prostate cancer tissue would provide an improved survival prediction for prostate cancer patients. PMID: 26731648
  33. calcineurin in astrocytes was activated by Amyloid beta, leading to IGFBP-3 release. PMID: 26637371
  34. Circulating levels of IGF-1, IGFBP-3 and their molar ratio were not associated with the risk of occurrence of colorectal adenoma PMID: 26388613
  35. Independent of obesity, high insulin levels but reduced levels of IGFBP-3 were associated with increased lung cancer risk in current smokers. PMID: 27071409
  36. IGFBP-3 levels after ischemic stroke may independently predict functional outcome after one year. PMID: 26069074
  37. -202 A/C IGFBP3 polymorphisms did not show any consistent association with clinical and laboratory features of acromegalic patients even after treatment. PMID: 25552351
  38. polymorphism in IGFBP-3 rs2854744 A>C might be a potential predictor of esophageal squamous cell carcinoma risk and patient survival PMID: 26349977
  39. Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-beta. PMID: 26216267
  40. Authors demonstrate that IGFBP3 is a direct TAp73alpha (the p73 isoform that contains the trans-activation domain) target gene and activates the expression of IGFBP3 in actively proliferating cells. PMID: 26063735
  41. Methylation of IGFBP-3 in colorectal cancer was identified to be significantly associated with risk of recurrence. PMID: 25822686
  42. Data indicate that IGF binding protein-3 (IGFBP-3) reduced transcription of a variety of integrins, especially integrin beta4. PMID: 25945837
  43. Serum IGFBP3 was increased in hepatocellular carcinoma patients compared to patients with liver cirrhosis, but lower than in healthy controls. PMID: 26068014
  44. The current meta-analysis suggests that the IGFBP-3 C2133G polymorphism may confer susceptibility to colorectal cancer. [Meta-analysis] PMID: 25966104
  45. In women with normal somatotroph function, IGFBP3 levels do not change in the first trimester of pregnancy. PMID: 25179796
  46. Loss of IGFBP3 expression is associated with Colorectal Cancer. PMID: 25987030
  47. IGFBP-3 polymorphism is not a cause of delayed infancy-childhood transition in idiopathic short stature children. PMID: 25742716
  48. The functional IGFBP3 A-202C polymorphism may influence the susceptibility and progression of breast cancer in the Chinese population. PMID: 25960224
  49. Results suggest that immediately postexercise testosterone and IGFPB-3 responses are significantly increased after endurance training followed by strength training but not after strength training followed by endurance training. PMID: 25028991
  50. These findings indicate that IGFBP-3 enhances etoposide-induced cell growth inhibition by blocking the NF-kappaB signaling pathway in gastric cancer cells. PMID: 25662950

Show More

Hide All

Subcellular Location Secreted
Tissue Specificity Expressed by most tissues. Present in plasma.
Database Links

HGNC: 5472

OMIM: 146732

KEGG: hsa:3486

STRING: 9606.ENSP00000370473

UniGene: Hs.450230

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1